NASDAQ · EDAP
Healthcare · Medical - Devices
$4.32
Down-$0.03 (-0.52%)
Updated Nov 3, 2026, 6:56 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · EDAP
1M range · 0 trading sessions · Daily adjusted prices
EDAP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning EDAP.
Company
Market Activity
Research & News
EDAP research
Company profile and research snapshot.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 9, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 4, 2025 | Jefferies | Hold | — |
| Mar 28, 2025 | Piper Sandler | Overweight | — |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 29, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · May 29, 2026
The Company also announced its intention to report and classify its Extracorporeal Shock Wave Lithotripsy ("ESWL") and Distribution operating segments as discontinued operations in the Company's financial statements
Finnhub · May 15, 2026
Edap TMS SA:Telix announces collaborations to explore PSMA-PET imaging in emerging prostate cancer treatment approaches....
Benzinga · May 15, 2026
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
Benzinga · May 14, 2026
EDAP TMS S.A. (NASDAQ:EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited ("Telix") to explore joint clinical research activities and physician education focused on the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EDAP.
No results
No recent SID articles mention EDAP.
